Why Are Indaptus Therapeutics Shares Shooting Higher On Wednesday?

The United States Patent and Trademark Office has issued a notice of patent allowance to Indaptus Therapeutics Inc's INDP platform technology.
The patent provides broad protection for applying the Company's platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.
Single-agent therapeutics derived from the Indaptus platform has produced significantly broader activity than the standard of care treatment in animal models of chronic hepatitis B and HIV infection.
Previously known as Intec Pharma Ltd, Indaptus merged with Decoy Biosystems Inc and completed a $30 million private placement.
The Company started trading under the new ticker in August.
Price Action: INDP stock trading was halted twice before the stock reached 171% higher at $19.20 during the market session on the last check Wednesday.